Patent ID: 11903968
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An engineered immune cell,
wherein said engineered immune cell has been genetically modified by intracellular expression of a rare-cutting endonuclease selected from a TALEN, RNA-guided endonuclease, ZFN, meganuclease, and megaTAL that cleaves an endogenous polynucleotide sequence encoding a SERCA3 protein to inactivate the expression of the SERCA3 protein encoded by the endogenous polynucleotide sequence and interrupt calcium transport and signaling,
wherein said engineered immune cell further expresses a chimeric antigen receptor (CAR), and
wherein the inactivation of the expression of the protein results in increased proliferation of the engineered immune cell at low glucose level.